Specialty pharmacy's role in REMS, FDA's new drug safety program.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2009 AND VI 44 AND IP 10
Results: 14
1
2
Drug watch. Atherosclerosis and hypertension.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
3
New molecular entity. Vibativ.
- Published in:
- 2009
- Publication type:
- Journal Article
4
FDA actions in brief.
- Published in:
- 2009
- Publication type:
- Journal Article
5
Fampridine-SR: a potassium-channel blocker for the improvement of walking ability in patients with MS.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
6
Atherosclerosis and hypertension.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 312
- Publication type:
- Article
7
FDA leadership promotes scientific integrity, quality standards.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 310
- By:
- Publication type:
- Article
8
Specialty pharmacy's role in REMS, FDA's new drug safety program.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 300
- By:
- Publication type:
- Article
9
Fampridine-SR: A potassium-channel blocker for the improvement of walking ability in patients with MS.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 293
- By:
- Publication type:
- Article
10
New combination.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 292
- Publication type:
- Article
11
FDA actions in brief.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 291
- Publication type:
- Article
12
New formulation.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 290
- Publication type:
- Article
13
New molecular entity.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 290
- Publication type:
- Article
14
Pipeline preview.
- Published in:
- Formulary, 2009, v. 44, n. 10, p. 290
- Publication type:
- Article